Perioperative Care Selection of Prophylactic Antibiotic — First OR Second Generation Cephalosporin This measure is to be reported each time a surgical procedure with the indications for a first or second generation cephalosporin antibiotic is performed during the reporting period. Measure description What if this process or outcome of care is not Percentage of surgical patient
Neurology medical group of diablo valley
Neurology Medical Group of Diablo Valley
400 Taylor Blvd. Ste 301
Pleasant Hill, CA 94523
Janet F. Hornstein Lin , MD
American Board of Psychiatry and Neurology - Neurology (Diplomate) National Board of Medical Examiners (Diplomate) Licensure
MD - New Jersey College of Medicine & Dentistry, Newark, NJ BA - Literature, Antioch College, Yellow Springs, OH Residencies and Internships
Chief Resident - Neurology, New Jersey College of Medicine & Dentistry, Newark, NJ July 1980 – June 1981 Resident - Neurology, New Jersey College of Medicine & Dentistry, Newark, NJ Internship – Internal Medicine, New Jersey College of Medicine & Dentistry, Newark, July 1977 – June 1978 NJ Professional Societies
Alameda-Contra Costa Medical Association Experience
Private Practice of Neurology - Neurology Medical Group of Diablo Valley, Walnut Appointments
Chairperson & Member - Bylaws Committee, John Muir Medical Center, Walnut Creek, CA Chairperson & Member - Ethics Committee, John Muir Medical Center, Walnut Creek, CA Part-time Lecturer - School of Optometry, University of California Berkeley, Berkeley, 1996 CA Co-Director - Neurosciences Intensive Care Unit, John Muir Medical Center, Walnut Creek, CA Member - ICU Comittee, John Muir Medical Center, Walnut Creek, CA Neuro Section Chair - John Muir Medical Center, Walnut Creek, CA Member - Neuro ICU Committee, John Muir Medical Center, Walnut Creek, CA Medical Consultant - Tri-Valley Rehabilitation Program, Danville, CA Co-Chairperson - Annual Joint Ethnics Seminar, John Muir Medical Center & Mt.
Current Hospital Affiliations
John Muir Medical Center - Walnut Creek, CA
Mt. Diablo Medical Center - Concord, CA
Presentations & Publications
Lin J FH, "Introduction to Fragile X Syndrome for Parents." Dev Brain Dysfunction, 8: 359-362, 1995.
A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the
Efficacy and Safety of Betaseron 250g Subcutaneously Every Other Day with Avonex 30g Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex (ABOVE) Medical Index for Neuromuscular Data (MIND) Registry Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain "Topamax Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy." SUBINVESTIGATOR A double-blind, active and placebo-controlled study of Aggrenox® vs. Clopidogrel + aspirin, with and without Micardis® (PRoFESS) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Efficacy and Safety of Intravenous NXY-059 In Acute Ischemic Stroke (SAINT) A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanirole versus Placebo in Patients with Early Parkinson's Disease E2020-A001-319 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX ® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS) (PROOF) Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Phase I, A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients With Recent Ischemic Stroke A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole versus Placebo or Ropinerole in Patients with Early Parkinson’s Disease Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson’s Disease: PNU-95666E Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, With 18 Months Follow-up. (MATCH) A Randomized, Placebo-Controlled, Three Treatment Arm Study to Determine the Safety and Efficacy of Argatroban Injection in Patients with Acute Ischemic Stroke Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion and FLAIR Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke. (ARTIST MRI) Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate 2001 - 2003 Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo. (ARTIST +) Phase III Multicenter, Double-Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson’s Disease in Patients Treated with L-Dopa or Dopamine Agonist Phase II, 12 Week, Randomized, Double-Blind, Placebo Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer’s Disease Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) Acute Ischemic Stroke Protocol 161-106, Phase II Lamictal® in Combination with Newer and Older Antiepileptic Drugs and as Mono- therapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: Trial to Assess and Refine Global Epilepsy Treatment)” "Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO), Phase III." 1999 – 2001 “A Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study 1999 – 2000 of Hu23F2G (LeukArrest ™) in Patients with Acute Ischemic Stroke.” “The Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer’s Disease.” Pregabalin BID, Open-Label, Add-On Trial: "An Open-Label, Multicenter, Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures." Pregabalin BID Add-On Trial: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures." "A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of Prosaptide When Administered Daily for 28 Days by Subcutaneous Injection on Diabetic Painful Neuropathy in Patients with Type 1 or Type 2 Diabetes Mellitus." The Acute Stroke Study in Ischemic Stroke (Class-I): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Efficacy and Safety of IV Compound Compared to Placebo in Patients with Acute Ischemic Stroke." The Acute Stroke Study in Acute Intracerebral Hemorrhage (Class-H): A Double-Blind, 1997 - 1999 Parallel-Group, Multinational, Multicenter Study of Safety of IV Compound Compared to Placebo in Patients with Acute Intracerebral Hemorrhage." The Acute Stroke Study in t-PA Treated Ischemic Stroke (Class-T): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Safety of IV Compound Compared to Placebo in Patients Treated with t-PA (Tissue Plasminogen Activator) for Acute Ischemic Stroke." An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d.(12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting." "Enlimomab Acute Stroke Study, Phase III."
CRITERIOS QUE SE DEBEN DE TOMAR EN CUENTA PARA CALIFICAR LA DISCIPLINA CRITERIOS Aporta activamente con su comportamiento en la formación de valores. Cumple a cabalidad con las disposiciones del plantel. Se preocupa por el grupo. Es proactivo en su interacción con el grupo; genera ideas y trabaja por cumplirlas. Muestra solidaridad, generosidad y demás características de liderazgo po